share_log

Flora Growth Applauds Launch of German Cannabis Pilot Programs

Flora Growth Applauds Launch of German Cannabis Pilot Programs

Flora Growth讚揚德國大麻股試點項目的啓動
newsfile ·  2024/12/12 21:17

Flora Intends to Submit Applications for Upcoming Cannabis Pilot Programs Run by BMEL

Flora計劃向BMEL提交即將舉行的大麻股試點項目的申請

Fort Lauderdale, Florida--(Newsfile Corp. - December 12, 2024) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company") today announced its intention to submit applications for participation in upcoming cannabis pilot programs in Germany to the Federal Ministry for Agriculture and Food ("BMEL"). These programs aim to effectively reduce the illicit market, expand health prevention, and provide an objective foundation for ongoing discussions surrounding cannabis.

佛羅里達州勞德代爾堡--(新聞文件CORP - 2024年12月12日)- Flora Growth Corp.(納斯達克:FLGC)(FSE:7301)("Flora"或"公司")今天宣佈其計劃向德國聯邦農業和食品部("BMEL")提交參與即將舉行的大麻股試點項目的申請。這些項目旨在有效減少非法市場,擴大健康預防,併爲圍繞大麻的持續討論提供客觀基礎。

Leading this endeavor will be Sammy Dorf, Executive Chairman, and Manfred Ziegler, Managing Director for Germany. Prior to joining the Company, Mr. Dorf played a key role in obtaining over 40 licenses across 14 U.S. states, including Illinois, Maryland, Nevada, Pennsylvania, and Ohio during his tenure at Verano Holdings. Assisting Mr. Ziegler will be TruHC's executive team, led by Hendrik Knopp who won the first tender for the cultivation of medical cannabis in Germany for Tilray (formerly Aphria).

這項工作的領導者將是執行董事會主席Sammy Dorf和德國總經理Manfred Ziegler。在加入公司之前,Dorf先生在Verano Holdings任職期間,發揮了在14個美國州(包括伊利諾伊州、馬里蘭州、內華達州、賓夕法尼亞州和俄亥俄州)獲得超過40個許可證的關鍵作用。協助Ziegler先生的是TruHC的執行團隊,由Hendrik Knopp領導,他贏得了德國Tilray(前身是Aphria)醫療大麻的首次種植招標。

"The German market represents a significant opportunity for Flora to showcase our expertise and drive innovation. We are excited about the potential of these pilot programs to advance cannabis and inform future policy decisions in Germany," said Clifford Starke, Chief Executive Officer. "With our background deeply rooted in leading the German medical market and the recent appointment of Sammy Dorf as our Executive Chairman earlier this week, we are extremely well positioned. Sammy's experience in successfully navigating the U.S. licensing landscape will be valuable as we pursue these opportunities in Germany."

首席執行官Clifford Starke表示:「德國市場爲Flora展示我們的專業知識和推動創新提供了重要機會。我們對這些試點項目推動大麻的潛力以及爲德國未來的政策決策提供信息感到興奮。」他還說道:「我們的背景深深植根於德國醫藥市場,Sammy Dorf本週早些時候被任命爲我們的執行董事會主席,使我們在這個領域極具競爭優勢。Sammy在成功駕馭美國許可環境方面的經驗將對我們在德國追求這些機會非常有價值。」

"Beyond the THC-infused beverage opportunity, we could not be more excited to finally enter the German legal market, of which we were the pioneers. We believe our history in the country will allow us to secure participation in these pilot programs and contribute to the responsible development of the German cannabis market," noted Sammy Dorf, Executive Chairman.

執行董事會主席Sammy Dorf指出:「除了含有THC的飲料機會外,我們對最終進入德國合法市場感到無比興奮,而我們在這一領域曾是開創者。我們相信我們在這個國家的歷史將使我們能夠確保參與這些試點項目,併爲德國大麻市場的負責任發展做出貢獻。」

The Company believes that its active participation in these pilot programs will not only contribute significantly to the advancement of cannabis but also solidify Flora's position as a leader in the German medical cannabis market.

公司相信,積極參與這些試點項目不僅將對大麻的進步做出重大貢獻,還將鞏固Flora在德國醫療大麻市場的領導地位。

About Flora Growth Corp.

關於Flora Growth CORP。

Flora Growth Corp.'s mission is to become the leading NASDAQ small-cap international cannabis company. Flora is a cannabis-focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution around the world. For more information on Flora, visit .

Flora Growth CORP.的使命是成爲納斯達克小型國際大麻公司的領導者。Flora是一家專注於大麻的消費品領導者和藥品分銷商,爲所有50個州和28個國家提供服務,在全球擁有超過20,000個分銷點。欲了解更多關於Flora的信息,請訪問。

Investor Relations:

投資者關係:

Investor Relations ir@floragrowth.com

投資者關係 ir@floragrowth.com

Clifford Starke Clifford.Starke@floragrowth.com

Clifford Starke Clifford.Starke@floragrowth.com

Media:

媒體:

media@floragrowth.com

media@floragrowth.com

Cautionary Statement Concerning Forward-Looking Statements

關於前瞻性聲明的警示性聲明

This press release contains "forward-looking statements," as defined by U.S. federal securities laws. Forward-looking statements reflect Flora's current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words "believe," "expect," "anticipate," "will," "could," "would," "should," "may," "plan," "estimate," "intend," "predict," "potential," "continue," and the negatives of these words and other similar expressions generally identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding: the Company's ability to successfully submit applications for participation in upcoming cannabis pilot programs in Germany; the Company's belief that it is well-positioned to contribute meaningfully to these initiatives; the Company's belief that Mr. Dorf's experience will be invaluable in pursuing these opportunities in Germany; the Company's confidence that it can successfully secure participation in these pilot programs and contribute to the responsible development of the German cannabis market; and the Company's ability to achieve its business objectives. Such forward-looking statements are subject to various and risks and uncertainties, including those described under section entitled "Risk Factors" in Flora's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on March 28, 2024, as such factors may be updated from time to time in Flora's periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov/edgar. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora's filings with the SEC. While forward-looking statements reflect Flora's good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based on information currently available to Flora (or to third parties making the forward-looking statements).

本新聞稿包含美國聯邦證券法所定義的「前瞻性陳述」。前瞻性陳述反映了弗洛拉在當時對未來事件的當前預期和預測,因此涉及不確定性和風險。"相信"、"期待"、"預期"、"將"、"可能"、"應該"、"可能"、"計劃"、"估計"、"打算"、"預測"、"潛在"、"繼續"以及這些詞的否定形式和其他類似表達一般標識前瞻性陳述。這些前瞻性陳述包括但不限於以下陳述:公司成功提交參與即將進行的大麻試點項目的申請的能力;公司相信其能在這些倡議中做出重要貢獻;公司相信多夫先生的經驗在尋求這些在德國的機會時將是無價的;公司相信能夠成功確保參與這些試點項目併爲德國大麻市場的負責任發展做出貢獻;以及公司實現其業務目標的能力。這些前瞻性陳述受到各種風險和不確定性的影響,包括在2024年3月28日向美國證券交易委員會(「SEC」)提交的弗洛拉年度報告10-k表格中標題爲「風險因素」部分所描述的風險,這些因素可能會隨時在弗洛拉定期提交給SEC的文件中進行更新,這些文件可以在SEC網站www.sec.gov/edgar上訪問。因此,可能存在或將存在重要因素,可能導致實際結果或成果與這些陳述中所指示的顯著不同。這些因素不應被視爲詳盡無遺,並且應與此發佈的其他警示性陳述和弗洛拉向SEC提交的文件一起閱讀。雖然前瞻性陳述反映了弗洛拉的善意信念,但它們並不是對未來表現的保證。弗洛拉不對公開更新或修訂任何前瞻性陳述以反映基本假設或因素、新信息、數據或方法、未來事件或此新聞稿日期之後的其他變化承擔任何義務,除非法律另有要求。您不應對基於弗洛拉(或作出前瞻性陳述的第三方)當前可用的信息的任何前瞻性陳述寄予過高的信任。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論